NCT05335473招募中1 期
Phase I b/ II Clinical Study of Iribrine Mesylate Plus Tucidinostat in the Treatment of HR+/HER2- Locally Relapsed or Metastatic Breast Cancer After Previous CDK4/6 Inhibitor Failure
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 87
- 试验地点
- 1
- 主要终点
- DLT for phaseⅠb
研究概览
简要总结
To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer
详细描述
To explore the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of the regimen of Eribulin plus Tucidinostat , and to initially explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to be enrolled:
- •Age ≥18 years and ≤75 years at the time of signing the informed consent;
- •The physical status score of the Eastern Oncology Consortium (ECOG) was ≤2 points;
- •Confirmed by pathology as HR+/HER2- (according to American College of Clinical Oncology/American College of Pathologists guidelines) (Note: HER2 feminine is defined as ①IH0; IHC1+; Locally advanced or metastatic IHC2+ : FISH-) Sexual female breast cancer patients, not suitable for radical treatment of the purpose of surgery or radiotherapy;
- •Proving that endocrine therapy is difficult to treat or resistant to endocrine therapy;
- •Used 1-2 chemotherapy regiments in the advanced stage;
- •Received at least one taxane and CDK4/6 inhibitor (including unmarketed ones) at any stage;
- •If a patient in the early stage relapses within 12 months of adjuvant chemotherapy (new), it can be counted as one advanced chemotherapy line Number;
- •The total number of treatment lines in the late stage ≤3 lines;
- •At least 1 measurable lesion was present according to RECIST1.1; External radiation therapy (EBRT) or local area treatment (such as radiofrequency ablation) of the lesion must show evidence of disease progression (according to RECIST 1.1), can be used as target lesion;
- •Life expectancy ≥3 months;
- •The functional level of the organ must meet the following requirements:
- •Blood routine: ANC≥1.5×109/L (no growth factor used within 14 days); PLT 100 x 109 or higher/L (within 7 daysNo corrective treatment was used); Hb≥100 g/L(no corrective treatment was used within 7 days);
- •Blood biochemistry: TBIL≤1.5×ULN; ALT and AST≤3 x ULN; Glutamine transpeptidase GGT≤2.5×ULN; If liver metastasis exists, ALT and/or AST≤5×ULN; Glutamine transpeptidase GGT≤5×ULN; Urea, urea nitrogen (BUN), creatinine (Cr) ≤1.5×ULN;
- •Cardiac color ultrasound: LVEF≥50%;
- •12-lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for male <450ms, female<470 ms.
- •The time interval between the end of the last antitumor therapy and the first administration of the study drug meets the following requirements: surgery The interval must be ≥4 weeks (minor surgery, such as tumor biopsy, thoracopuncture, or intravenous catheter placement, is not limited); Recovery of adverse reactions to previous antitumor therapy (radiotherapy, chemotherapy, targeting) to ≤ Grade 1 (phase Ib required patients A washout period of 7-14 days after natural recovery without symptomatic drugs or symptomatic treatment).
- •Voluntarily agrees to and signs a written informed consent and is willing and able to comply with all aspects of the test protocol,The patient may withdraw consent at any time without prejudice to his rights and interests.
排除标准
- •Subjects will not be enrolled if they meet any of the following criteria:
- •Receiving neoadjuvant or adjuvant therapy containing Iribulin within one year prior to treatment initiation;
- •Patients with recurrent or metastatic breast cancer who have failed or responded to previous treatment with Iribulin (achieved CR/PR/SD), but tumor progression within 6 months after cessation of aribulin therapy;
- •Patients who have received any HDAC inhibitor at any time in the past;
- •Participated in clinical trials of unmarketed drugs within 4 weeks before enrollment;
- •Exclude subjects with brain or subdural metastases. Unless the patient has completed local treatment and is stable on imaging Those who had maintained the condition for at least 4 weeks, had stopped systemic sex hormone therapy and had stable symptoms for at least 4 weeks were included(By comparing head enhancement CT or MRI performed during screening with head enhancement performed at least 4 weeks earlier CT or MRI to determine the stability of the lesion);
- •Before screening, the toxicity of the original treatment regimen had not recovered, and there were still more than grade 1 toxic reactions (CTCAE5.0);
- •Clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow,Chronic diarrhea, intestinal obstruction, etc);
- •Severe/uncontrolled disease or active infection;
- •Severe cardiovascular injury (greater than NYHA Class II congestive heart failure) History), unstable angina pectoris or myocardial infarction within the past 6 months, or severe arrhythmia;
- •Subjects with allograft requiring immunosuppressive therapy.
- •Subject has active hepatitis (hepatitis B reference: HBsAg positive and HBV DNA≥500 IU/ml; cLiver reference: HCV antibody positive and HCV virus copy number > upper limit of normal); Known human immunodeficiency disease Hiv-positive subjects.
- •Had other malignancies within the previous 5 years, excluding cured papillary thyroid carcinoma and in situ cervix Carcinoma, skin basal cell carcinoma or skin squamous cell carcinoma;
- •Subjects with hypersensitivity to softin B and/or softin B chemical derivatives.
- •Pregnant and lactating women, fertile women who have tested positive for baseline pregnancy tests,or were unwilling to use effective contraception throughout the trial period and within 90 days after the last administration of the study drug age patients;
- •The investigator considers the subject unfit for any medical condition to enter the study.
研究组 & 干预措施
Eribulin plus Tucidinostat
Experimental
phase 1b： 3+3 trial design will be used for Tucidinostat dose escalation cohorts phase 2: Eribulin+Tucidinostat
干预措施: Eribulin and Tucidinostat (Drug)
结局指标
主要结局
DLT for phaseⅠb
时间窗: 1 year
Dose-limiting toxicity defined as any Grade 4 hematological toxicity and any \> Grade 3 non-hematologic toxicity.
Progression-Free Survival (PFS) for phase Ⅱ
时间窗: 2 years
PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause.
MTD for phaseⅠb
时间窗: 1 year
Maximum tolerated dose is highest dose level in which 6 patients treated with at most 1 experiencing DLT.
次要结局
- adverse events (AE)(2 years)
- Clinical Benefit Rate (CBR)(2 years)
- Overall Survival (OS)(2 years)
- Duration of Response (DOR)(2 years)
- Progression-Free Survival (PFS) for phaseⅠb(2 years)
- Objective Response Rate (ORR)(2 years)
研究者
Min Yan, MD
Chief Physician
Henan Cancer Hospital
研究点 (1)
Loading locations...
相似试验
撤回
1 期
Tucatinib + Abemaciclib + Herceptin for HER2+ MBCBreast CancerNCT03846583Dana-Farber Cancer Institute
已完成
2 期
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast CancerRecurrent Breast CarcinomaStage IV Breast CancerNCT01908101University of Washington86
已完成
2 期
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical CancerRecurrent Cervical CancerStage IIIA Cervical CancerStage IIIB Cervical CancerStage IVA Cervical CancerStage IVB Cervical CancerNCT01676818University of Southern California32
进行中（未招募）
2 期
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer PatientsMetastatic Breast CancerNCT05833919Consorzio Oncotech122
终止
2 期
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast CancerHER2-positive Breast CancerMetastatic Breast CancerNCT01912963Dana-Farber Cancer Institute32